Abstract
Mpox, formerly monkeypox, is a viral zoonotic disease caused by the monkeypox virus (MPXV). MPXV, which is taxonomically divided into clades I and II, was declared a Public Health Emergency of International Concern for the second time in August 2024 due to rapid geographic expansion of clade I viruses including the newly identified clade Ib [1]. With a unique set of genomic mutations and sustained human-to-human transmission, clade Ib has rapidly spread throughout the eastern Democratic Republic of the Congo as well as neighboring non-endemic regions outside the African continent [2–6]. Currently, there is a lack of comparative genomic data with which to address potential zoonotic transmissibility and pathobiology of clade Ib. Here we show MPXV clades I and II share a core genome composed of 68 protein-coding genes which are common in the genomes of other poxviruses such as camelpox, cowpox, and vaccinia. The first documented and all subsequently examined isolates of clade Ib lack the gene pair OPG032 and OPG033, which encode the complement control protein (a vaccinia ortholog associated with virulence), and a Kelch-like protein, respectively. The genomic rearrangement of MPXV suggests a functional evolution that might play an important role in the pathobiology of the novel clade Ib virus. Our results lay the groundwork to exploit the genomic of elements of MPXV as potential targets for therapeutics development/repurposing, vaccine design, and molecular diagnostic expansion, as well as to uncover the viral diversity, and zoonosis of MPXV.
Competing Interest Statement
The authors G.S.M, A.K., M.D., P.K, and D.J.K. are shareholders of the company BioForge Canada Limited. The authors declare the interests of the company had no impact in the study.
Funding Statement
This work was supported by awards from the Canadian Institutes of Health Research, the Mpox Rapid Research Funding initiative (CIHR MZ1 187236), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK), Li-Ka Shing Foundation (DJK), and Dalhousie Medical Research Foundation (DJK). Research in the Archibald Lab is supported by the Natural Sciences and Engineering Research Council of Canada (RGPIN- 2019-05058) and the Gordon and Betty Moore Foundation (GBMF5782). The genomes were generated through DRC national genomic surveillance activities which are supported by many initiatives such as Africa CDC Pathogen Genomics Initiative (Africa PGI) (grants BMGF-INV-018278, INV-033857, Saving Lives and Livelihoods program, and NU2HGH000077); AFROSCREEN project (grant agreement CZZ3209, coordinated by ANRS-MIE Maladies infectieuses emergentes in partnership with Institut de Recherche pour le Developpement [IRD] and Pasteur Institute) funded by Agence Francaise de Developpement; PANAFPOX project funded by ANRS-MIE; Belgian Directorate-General Development Cooperation and Humanitarian Aid and the Research Foundation, Flanders (FWO, grant number G096222 N to L.L.); Department of Defense, Defense Threat Reduction Agency, and Monkeypox Threat Reduction Network; USDA Non-Assistance Cooperative Agreement #20230048; International mpox Research Consortium (IMReC), through funding from the Canadian Institutes of Health Research and International Development Research Centre (grant no. MRR-184813); and E.K.-L. received a PhD grant from the French Foreign Office.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
In this revised version, we included in our report the deletion of the gene OPG033, which is also a genetic feature of the novel MPXV clade Ib virus.
Data Availability
All data produced in the present work are contained in the manuscript
